Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 3, 2003, Pages 382-391

  Carraro, Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Clinical laboratory methods; Coagulation disorders; Coagulation inhibitors; Guidelines; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; FIBRINOLYTIC FACTOR; GLYCOPROTEIN; HEPARIN COFACTOR II; HISTIDINE; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; BLOOD SAMPLING; BLOOD STORAGE; CEREBROVASCULAR DISEASE; CLINICAL LABORATORY; DIAGNOSTIC TEST; DYSFIBRINOGENEMIA; FULMINATING PURPURA; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; INHERITANCE; LABORATORY TEST; MEDICAL DECISION MAKING; NEWBORN DISEASE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; SCREENING TEST; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

ANTITHROMBIN III DEFICIENCY; DIAGNOSTIC TESTS, ROUTINE; FACTOR V; FEMALE; HUMANS; LABORATORIES; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; THROMBOPHILIA;

PURPURA;

EID: 0037253814     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.059     Document Type: Review

References (93)

1. Laffan M, Tuddenham E. Assessing thrombotic risk. Br Med J 1998; 317:520-3.
2. Nordstrom M, Lindblad B , Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232:155-60.
3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998; 158:585-93.
4. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulation response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-8.
5. Bertina RM, Koeleman BPC, Koster T Rosendaal FR, Dirven RJ, de Roonde H, et al. Mutation in blood coagulation factor V associated with resistance to protein C activated. Nature 1994; 369:64-7.
6. Poort RS, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-703.
7. Baglin T. Thrombophilia testing: what do we think the tests mean and what should we do with the results? J Clin Pathol 2000; 53:167-70.
8. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82:610-9.
9. Basic guidance on writing about diagnostics to Bandolier. www.jr2.ox.ac.uk/bandolier/booth/diagnos/Diagessy.html
10. Bandolier rules for diagnostic tests. www.jr2.ox.ac.uk/bandolier/band26/b26-2.html
11. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87:106-12.
12. Van den Belt AGM, Huisman MV, Hirsh J. Familial thrombophilia: a review analysis. Clin Appl Thromb Hemost 1996; 2:227-36.
13. Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman MV, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999; 94:3702-6.
14. Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, et al. Antithrombin III mutation database: first update. Thromb Haemost 1993; 70:361-9.
15. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J, the EMET Group. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism-results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb Haemost 1997; 77:444-51.
16. Koster T, Rosendaal FR,, Briet E, Van der Meer FJM, Colly LP, Trienekens PH, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85:2756-61.
17. Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73:87-93.
18. Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317:991-6.
19. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76:651-62.
20. Faioni EM, Valsecchi C, Palla A, Taioli E, Razzari C, Mannucci PM. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997; 78:1343-6.
21. Dykes AC, Walker ID, McMahon AD, Islam SIAM, Tait C. A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex, and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113:636-41.
22. Van der Meer FJM, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78:631-5.
23. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-4.
24. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. J Am Med Assoc 1997; 277:1305-7.
25. Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-6.
26. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisemberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-7.
27. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-8.
28. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of 20210 G to A prothrombin variant. Thromb Haemos 1998; 79:706-8.
29. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, et al. Prevalence of 20210A allele of the prothrombin gene in venous thromo-embolism patients. Thromb Haemost 1998; 80:49-51.
30. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men. Circulation 1999; 99:999-1004.
31. Den Heijer M, Rosendaal FR, blom HJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80:874-7.
32. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90:1-11.
33. Den Heijer M, Koster T, Blom JH, Bos GMJ, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Eng J Med 1996; 334:759-62.
34. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, et al. Hyperhomocysteinemia and deep-vein thrombosis: a case-control study. Thromb Haemost 1996; 76:883-6.
35. Engbertsen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56:142-50.
36. Shigekiyo T, Uno Y, Tomonari A, Satoh K, Hondo H, Ueda S, et al. Type I plasminogen deficiency is not a risk factor for thrombosis. Thromb Haemost 1992; 67:189-92.
37. Sartori MT, Patrassi GM, Theodoridis P, Perin A, Pietrogrande F, Girolami A. Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistic analysis in 20 kindreds. Blood Coag Fibrinolysis 1994; 5:889-93.
38. Bertina RM, van der Linden K, Engesser L, Muller HP, Brommer EJP. Hereditary heparin co-factor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987; 57:196-200.
39. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis. Blood 2000; 95:2855-9.
40. Koster T, Rosendaal FR, Vandenbroucke JP, Briet E. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia study. Br J Haematol 1994; 87:422-5.
41. Kraaijenhagen RA, in't Anker PS, Koopman MMW, Reitsma PH, Prins MH, van den Hende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83:5-9.
42. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-5.
43. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95:3678-82.
44. Meijers JCM, Tekelemburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI is a risk factor for venous thrombosis. N Eng J Med 2000; 342:696-701.
45. De Moerloose P, Bounameaux HR, Mannucci PM. Screening tests for thrombophilic patients: which tests, for which patient, by whom, when, and why? Sem Thromb Hemost 1998; 24:321-7.
46. Simioni P, Tormene D, Prandoni P, Zerbinati P, Gavasso S, Cefalo P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a perspective cohort study. Blood 2002; 99:1938-42.
47. Vanderbroucke JP, van der Meer JM, Hemerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? Br Med J 1996; 313:1127-30.
48. NCCLS. Collection, transport, and processing of blood specimens for coagulation testing and general performance of coagulation assays; approved guideline - 3rd ed. NCCLS document H21-A3; 1998, Wayne, PE.
49. Laxson CJ, Titler MG. Drawing coagulation studies from arterial lines: an integrative literature review. Am J Crit Care 1994; 1:16-24.
50. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 1997; 107:105-10.
51. O'Broin SD, Kelleher BP, Mc Partlin J, O'Gorman P, Browne M, Withe B, et al. Optimization of routine plasma homocysteine monitoring. Blood Coag Fibrinolysis 2000; 16: 1085-7.
52. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 2001; 86:1495-500.
53. Trossaert M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995; 73:163-4.
54. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512-28.
55. Dati F, Hafner G, Erbes H, Prellwitz W, Kraus M, Niemann F, et al. ProC Global: the first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43:1719-23.
56. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: part 2. Thromb Haemost 1996; 76:824-34.
57. Faioni EM, Franchi F, Asti D, Mannucci PM. Resistance to activated protein C mimicking dysfunctional protein C: a diagnostic approach. Blood Coag Fibrin 1996; 7:349-52.
58. De Moerloose P, Reber G, Bouviar CA. Spuriously low levels of protein C with a Protac activation clotting assay. Thromb Haemost 1988; 59:543.
59. Simioni P, Lazzaro AR, Zanardi S, Girolami A. Spurious protein C deficiency due to antiphospholipid antibodies. Am J Hematol 1991; 36:299-300.
60. Faioni EM, Valsecchi C, Palla A, Taioli E, Razzari C, Mannucci PM. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997; 78:1343-6.
61. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78:315-26.
62. Faioni EM, Franchi S, Asti D, Sacchi E, Bernardi E, Mannucci PM. Resistance to activated protein C in 9 thrombophilic families. Interference in a protein S functional assay. Thromb Haemost 1993; 70:1067-71.
63. Tripodi A, Chantarangkul V, Negri B, Mannucci PM. Standardisation of the APC resistance test. Effects of normalisation of results by means of pooled plasma. Throm Haemost 1998; 79:564-6.
64. Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77:332-5.
65. Freyburger G, Javorschi S, Labrouche S, Bernard P. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients. Thromb Haemost 1997; 78:1360-5.
66. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001 Mar-Apr; 3:139-48.
67. Grunewald M, Germowitz A, Beneke H, Guethner C, Griesshammer M. Coagulation factor II activity determination is not useful as a screening tool for the G20210A prothrombin gene allele. Thromb Haemost 2000; 84:141-2.
68. Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci PM, Cattaneo M. Multicenter study of homocysteine measurement. Performance characteristics of different methods. Influence of standards on interlaboratory agreement of results. Thromb Haemost 2001; 85:291-5.
69. Rossi E, Beilby JP, McQuillan BM, Hung J. Biological variability and reference intervals for total plasma homocysteine. Ann Clin Biochem 1999; 36:56-61.
70. Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Wight M, et al. Protein C activity in healthy volunteers - influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1993; 70:281-5.
71. Dykes AC, Walker ID, McMahon AD, Islam SIAM, Tait RC. A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency status. Br J Haematol 2001; 113:636-41.
72. http://ifcc-iupac.suite.dk/tah.htm, accessed on March 15th 2002.
73. Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97:775-84.
74. Pabinger I, Allaart CF, Hermans J, Briet E, Bertina RM. Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC subcommittee on protein C and protein S. Thromb Haemost 1992; 68:470-4.
75. Rodeghiero F, Tosetto A. The epidemiology of inherited thrombophilia: the VITA project Vicenza thrombophilia and atherosclerosis project. Thromb Haemost 1997; 78:636-40.
76. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160:49-52.
77. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913-6.
78. Kupferminc MJ, Eldor A, Steinman M, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilias in women with complications of pregnancy. N Engl J Med 1999; 340:9-13.
79. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000-3.
80. Grandone E, Margaglione M, Colaizzo D, D'Addedda M, Cappucci G, Vecchione G, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemostas 1997; 77:822-4.
81. Brenner B. Inherited thrombophilia and pregnancy loss. Thromb Haemos 1999; 82:634-40.
82. Gates S, Brocklehurst P. Cochrane Pregnancy and Childbirth Group. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews. Issue 1, 2002.
83. Paternoster DM, Stella A, Simioni P, Girolami A, Plebani M. Fibronectin and antithrombin as markers of pre-eclampsia in pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996; 70:33-9.
84. He S, Bremme K, Blomback M. Can the laboratory assay of protein C activity assist in monitoring the hemostatic function in pre-eclampsia? Blood Coagul Fibrinolysi. 1999; 10:127-32.
85. Brenner B, Lanir N, Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996; 92:999-1001.
86. Takamiya O, Kinoshita S, Niinomi K, Yoshioka K. Protein C in the neonatal period. Haemostasis 1989; 1:45-50.
87. Polack B, Pouzol P, Amiral J, Kolodie L. Protein C level at birth. Thromb Haemos 1984; 52:188-90.
88. Fok TF, Yin JA, Yuen PM. Comparison of antithrombin III, protein C and protein S levels in capillary and venous blood of newborn infants. Acta Paediatr 1992; 81:204-6.
89. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylentetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94:3678-82.
90. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosemberg N, Gitel S, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31:1283-8.
91. Voetsch B, Damasceno BP, Camargo ECS, Massaro A, Bacheschi LA, Scaff M, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemos 2000; 83:229-33.
92. Manco-Johnson MJ, Grabowski EF, Hellgreen E, Kemahli AS, Massicotte MP, Muntean W, et al. Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Communications Laboratory testing for Thrombophilia in Pediatric Patients. http://www.med.unc.edu/isth/perinatal/perinatalthrombophilia.htm, accessed on March 15th 2002.
93. Gunther G, Junker R, Strater R, Schobess R, Kurnik K, Heller C, et al. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke. 2000; 31:2437-41.